Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (SHA:600329)
China · Delayed Price · Currency is CNY 36.78
-0.43 (-1.16%)
Aug 11, 2026, 2:55 PM CST
SHA:600329 Revenue
Tianjin Pharmaceutical Da Ren Tang Group Corporation had revenue of 1.52B CNY in the quarter ending March 31, 2026, with 4.12% growth. This brings the company's revenue in the last twelve months to 4.98B, down -25.45% year-over-year. In the year 2025, Tianjin Pharmaceutical Da Ren Tang Group Corporation had annual revenue of 4.92B, down -32.70%.
Revenue (ttm)
4.98B
Revenue Growth
-25.45%
P/S Ratio
5.01
Revenue / Employee
1.28M
Employees
3,890
Market Cap
24.92B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.92B | -2.39B | -32.70% |
| Dec 31, 2024 | 7.31B | -915.58M | -11.14% |
| Dec 31, 2023 | 8.22B | -26.94M | -0.33% |
| Dec 31, 2022 | 8.25B | 1.34B | 19.42% |
| Dec 31, 2021 | 6.91B | 303.89M | 4.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.